Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

類似資料

• Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
  著者:: Galili, Naomi, 等
  出版事項: (2012)
• Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure
  著者:: Quddus, Fahd, 等
  出版事項: (2010)
• Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(®), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
  著者:: Raza, Azra, 等
  出版事項: (2009)
• Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
  著者:: Sekeres, Mikkael A., 等
  出版事項: (2008)
• An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
  著者:: Ebert, Benjamin L, 等
  出版事項: (2008)